Discovery of potent allosteric antibodies inhibiting EGFR

Discovery of potent allosteric antibodies inhibiting EGFR

In this work, we report the discovery of potent anti-epidermal growth factor receptor (EGFR) allosteric heavy-chain antibodies by combining camelid immunization and fluorescence-activated cell sorting (FACS). After immunization and yeast surface display library construction, allosteric clones were o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Léxane Fournier, Lukas Pekar, Birgitta Leuthner, Harald Kolmar, Lars Toleikis, Stefan Becker
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Allostery antibody discovery cancer therapy EGFR heavy-chain antibody triple-negative breast cancer
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2406548
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings
by: Maria Meira, et al.
Published: (2024-12-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma
by: Shanmugappiriya Sivarajah, et al.
Published: (2019-01-01)

Discovery and in vitro characterization of a human anti-CD36 scFv
by: Cecilia Mata-Cruz, et al.
Published: (2025-02-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity
by: Dafei Chai, et al.
Published: (2025-01-01)

Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation
by: Dale O. Starkie, et al.
Published: (2024-12-01)

Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models
by: Ying Jin, et al.
Published: (2025-02-01)

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
by: Pietro Paolo Vitiello, et al.
Published: (2025-02-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Allosteric Fluorescent Detection of Saccharides and Biomolecules in Water from a Boronic Acid Functionalized Arene Ruthenium Assembly Hosting Fluorescent Dyes
by: Alaa Maatouk, et al.
Published: (2024-12-01)

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer
by: Xiaojie Chu, et al.
Published: (2024-12-01)

Travailler avec François Gros à l’Institut Pasteur : l’allostérie, le récepteur nicotinique et la biologie du futur
by: Changeux, Jean-Pierre
Published: (2023-12-01)

Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies
by: Armin Sepp, et al.
Published: (2024-12-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery
by: Carolin Sophie Dombrowsky, et al.
Published: (2025-03-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
by: M. Biddle, et al.
Published: (2024-12-01)

Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01)

Predictive Value of Initial 18F-FDG PET/CT for Identifying EGFR and KRAS Mutations in Patients with Non-small-cell Lung Cancer
by: Ozge Vural Topuz, et al.
Published: (2024-11-01)

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
by: Da-yan Zhang, et al.
Published: (2025-01-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

Cross-Talk between NOK and EGFR: Juxtamembrane and Kinase domain interactions enhancing STAT3/5 signaling in breast cancer tumorigenesis
by: Yinyin Wang, et al.
Published: (2025-02-01)

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms
by: Marianne Bachmann Salvy, et al.
Published: (2024-12-01)

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY
by: Jill Feldman, MA, et al.
Published: (2025-03-01)

Electrostatic properties of human germlines and biodistribution of small biologics
by: Leticia Maria De Souza Cordeiro, et al.
Published: (2024-12-01)

Clinical significance of establishing a red blood cell alloantibody detection database
by: XIAO Xiao, et al.
Published: (2025-01-01)

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
by: Yuji Uehara, MD, et al.
Published: (2025-03-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context
by: Yuichi Adachi, et al.
Published: (2025-02-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
by: Ugochi Ebinama, et al.
Published: (2025-01-01)

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024-12-01)